Literature DB >> 12692371

Paronychia induced by gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor.

Junji Nakano, Mitsutaka Nakamura.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 12692371     DOI： 10.1111/j.1346-8138.2003.tb00387.x

Source DB:  PubMed          Journal:  J Dermatol        ISSN： 0385-2407            Impact factor:   4.005


× No keyword cloud information.
  4 in total

1.  A randomized phase 2 trial of the efficacy and safety of a novel topical povidone-iodine formulation for Cancer therapy-associated Paronychia.

Authors:  Kara D Capriotti; Milan Anadkat; Jennifer Choi; Benjamin Kaffenberger; Beth McLellan; Samuel Barone; Oluwaseun Kukoyi; Shari Goldfarb; Mario Lacouture
Journal:  Invest New Drugs       Date:  2019-06-26       Impact factor: 3.850

2.  Adverse events associated with anti-EGFR therapies for the treatment of metastatic colorectal cancer.

Authors:  M Fakih; M Vincent
Journal:  Curr Oncol       Date:  2010-07       Impact factor: 3.677

3.  Nail Changes Induced by Chemotherapeutic Agents.

Authors:  Neerja Saraswat; Aradhana Sood; Rajesh Verma; Dhramesh Kumar; Sushil Kumar
Journal:  Indian J Dermatol       Date:  2020 May-Jun       Impact factor: 1.494

4.  Dermatological Side Effects of Epidermal Growth Factor Receptor Inhibitors: 'PRIDE' Complex.

Authors:  Bhushan Madke; Prachi Gole; Prabhash Kumar; Uday Khopkar
Journal:  Indian J Dermatol       Date:  2014-05       Impact factor: 1.494
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.